NCT01534715 (Clinical Trial / IMGN529)

Study Title
IMGN529 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (NCT01534715)

Trial Description
The purpose of this study is to test the safety and tolerability of IMGN529 in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).

This trial is sponsored by ImmunoGen, Inc. [1]

Study Data

  • Condition: Lymphoma and Leukemia
  • Interventions:
    • Drugs used in this trial
      • IMGN529
  • Phase: I
  • Estimated Enrollment: 110
  • Start: January 2012
  • Estimated Primary Completion: December 2015
  • Last verified: June 2015

Study Schematic 

(Coming soon)


Last Editorial review: September 29, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.